ESMO 2021 Kidney Cancer

Viewing 1-20 of 29 articles

ESMO 2021: Antibiotic Therapy and Outcome from Nivolumab in Metastatic Renal Cell Carcinoma (mRCC) Patients: Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study

ESMO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ESMO 2021: Are Adjuvant Immune Checkpoint Inhibitors a Standard of Care for Operable High-Risk Urothelial and Kidney Cancer? No

ESMO 2021: Are Adjuvant Immune Checkpoint Inhibitors a Standard of Care for Operable High-Risk Urothelial and Kidney Cancer? Yes

ESMO 2021: Future Targets and Combinations for Metastatic Renal Cell Carcinoma

ESMO 2021: Current Status of Personalized Therapy in Metastatic Renal Cell Carcinoma

ESMO 2021: Is There an Optimal First-Line Combination Approach for Metastatic mRCC?

ESMO 2021: Invited Discussant: Modified Delivery of RCC Therapy: Can we Maintain Efficacy and Improve Quality of Life?

ESMO 2021: STAR: A Randomized Multi-Stage Phase II/III Trial of Standard First-Line Therapy (Sunitinib or Pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the Treatment of Locally Advanced And/or Metastatic RCC

ESMO 2021: Pembrolizumab Versus Placebo as Adjuvant Therapy for Patients with RCC: Patient-Reported Outcomes in KEYNOTE-564

ESMO 2021: Pembrolizumab vs Placebo As Adjuvant Therapy for Patients With Renal Cell Carcinoma: Patient-Reported Outcomes in KEYNOTE-564

ESMO 2021: Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced RCC: A Randomized Phase II Trial (PRISM)

ESMO 2021: Subsequent Therapy Following Pembrolizumab + Axitinib or Sunitinib Treatment for Advanced RCC in the Phase 3 KEYNOTE-426 Study

ESMO 2021: First-Line Nivolumab + Cabozantinib vs Sunitinib in Patients With Advanced RCC in Subgroups Based on Prior Nephrectomy in the CheckMate 9ER Trial

ESMO 2021: Pembrolizumab Monotherapy As First-Line Therapy in Advanced Non–Clear Cell RCC: Results After a Minimum of 34 Months of Follow-Up From KEYNOTE-427 Cohort B

ESMO 2021: Matching-Adjusted Indirect Comparison of Health-Related Quality of Life of Nivolumab plus Cabozantinib Versus Pembrolizumab plus Axitinib in Previously Untreated Advanced RCC

ESMO 2021: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell RCC: Results After a Minimum of 41 Months of Follow-up From KEYNOTE-427 Cohort A

ESMO 2021: Role of Prior Nephrectomy for Synchronous Metastatic RCC on Efficacy in Patients Treated with Avelumab + Axitinib or Sunitinib: Results from JAVELIN Renal 101

ESMO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell RCC

ESMO 2021: Antibiotic Therapy and Outcome from Nivolumab in Metastatic RCC Patients: Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study

1
2